The Option Trial (Ovarian Protection Trial in Oestrogen Non-Responsive Premenopausal Breast Cancer Patients Receiving Adjuvant or Neo-Adjuvant Chemotherapy) for breast cancer looked at hormone suppression using GNRH analogues and progestogens and examined the impact of this on fertility. Here, GNRH1 is linked to breast cancer.